{
    "nct_id": "NCT03438396",
    "official_title": "A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer",
    "inclusion_criteria": "Inclusion Criteria\n\n* Patients with extra-pelvic metastatic or recurrent cervical cancer including squamous cell, adenocarcinoma or adenosquamous histology who have experienced disease progressed on standard of care chemotherapy in combination with bevacizumab, if eligible.\n* Measurable disease according to RECIST v1.1 as assessed by IRC.\n* Age ≥ 18 years.\n* Acceptable renal function\n* Acceptable liver function\n* Acceptable hematological status\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* A negative serum pregnancy test for patients of reproductive potential.\n* All patients must provide a fresh or archival biopsy during screening.\n* Following receipt of verbal and written information about the trial, patients must provide signed informed consent before any trial-related activity is carried out.\n\nExclusion Criteria\n\n* Have received no more than 2 prior systemic treatment regimens for recurrent or metastatic cervical cancer.\n* Known past or current coagulation defects leading to an increased risk of bleeding;\n* Ongoing major bleeding\n* Active ocular surface disease\n* Known past or current malignancy other than the inclusion diagnosis.\n* Peripheral neuropathy grade ≥ 2\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}